it was not long before the side effects of these compounds aroused the interest of psychiatrists because they produced all the psychological manifestations described in the naturally occurring endocrine disorders. Since then the two disciplines of psychiatry and endocrinology have drawn closer together. There is now a great deal of evidence to show that not only do administered steroids and endocrine diseases involving the adrenal cortex produce psychological symptoms (58) but that emotional illnesses produce changes in the plasma and urinary corticosteroid levels.
In 1904 the idea of a neurohormone was suggested by T. R. Elliott (20) when he reported that sympathetic nerves released a substance like adrenaline at their endings. Cannon (12) later established verification of this suggestion and said that adrenaline was secreted by animals in response to fear and rage. Since then a great deal of investigation has gone into finding a possible relationship between biogenic amines and human emotions. The comparatively recent observation that the metabolism of noradrenaline, dopamine and serotonin could be influenced by psychopharmacological agents has stimulated research interest and important new information has been gathered about the cerebral amines and their function (68) .
Hormonal investigations into the affective disorders have principally centered around the activity of the adrenal cortex and the catecholamines. The authors feel that these hormone systemS! are disturbed in a particular direction, so in this paper they wish to propose the following hypothesis with regard to the biochemical disturbances in psychotic depression: 477 The association of certain critical periods in life such as puberty, pregnancy and the menopause with changes in mental state provoked speculation from the earliest times as to the possible effects of 'humors' on the mind. The first reported observation associating mental functions with endocrine disease was made by Platter in the 17th century -1602 (52) .
That the adrenals influence the functions of the brain has become increasingly more evident since Addison in 1855 (1) reported several cases of adrenal cortical insufficiency with psychological symptoms. A considerable interval of time elapsed before Hartmann in 1934 (29) administered adrenocortical extract and produced relief of the psychological symptoms occurring in Addison's disease. Then in 1941 Engel and Margolin (21) drew attention to the high incidence of psychiatric symptomatology occurring in this condition. Up until this time the early psychiatric changes described were considered by investigators to be the side effects of the accompanying endocrine disorder and their importance was minimized or ignored. This is surprising since Freud as early as 1905 (23) had referred to endocrinology as the biological next door neighbour of psychoanalysis and observed that certain mental disorders might eventually be treated successfully with hormones. However, with the introduction of adrenocorticotrophic hormone (ACTH) and cortisone into medical treatments a) that part at least of the hormonal disturbance in psychotic depressive illness is an imbalance between the adrenocortical steroids and the catecholamines whereby there is a relative or absolute deficiency in the steroids and biogenic amines of the brain and, b) that clinical recovery is induced when appropriate medication is administered to correct this biochemical disturbance. The first to study corticosteroids using modern biochemical methods in depressed patients were Board et at (6, 7) .
They found that severely depressed patients, especially those with intense suffering, retardation and inability to cry, had elevated plasma 17-hydroxycorticosteroid levels. In 1962 Gibbons and McHugh (25) measured plasma cortisol at weekly intervals in depressed patients and found a positive correlation between the steroid levels and the severity of the illness. During treatment there was a gradual lowering of the high initial corticosteroid levels and this coincided with clinical improvement. Gibbons (26) reported a combined study of plasma cortisol and cortisol secretion rate in 15 cases of depression. Those with the most severe depression had the greatest increase in secretion rate. A high correlation was also found between the plasma cortisol level and the cortisol secretion rate. However, a small number of patients failed to show this change in cortisol secretion and it was stated that significant depression could occur in some subjects without any increase in their adrenocortical activity.
Bunney et at, 1965 (8) reported longitudinal studies of urinary 17-OHCS and continuous behavioural ratings in 17 depressed patients. The authors attempted to correlate psychological fluctuations during illness with fluctuations in urinary 17-0HCS excretion. Days of maximum emotional disturbance were compared with days of minimum disturbance. It was noted by the investigators that the days of maximum emotional disturbance were accompanied by almost as much anxiety as depression. The correlations for the group were not significant, but in a sub-group of twelve patients they were. In addition, about one-third of the patients had normal or sub-normal urinary 17-0HCS which suggested to the authors the possibility of a depressive subgroup with low 17-hydroxycorticosteroid excretion. In a different paper, Bunney et at (9) studied crisis periods in patients with psychotic depression. During these episodes of turmoil, which were characterized by great anxiety, there was substantial elevation of the urinary 17-hydroxycorticosreroids.
The findings of these and other studies (24, 18, 45) are in general agreement that there is a marked elevation of plasma cortisol and urinary 17-hydroxycorticosteroid levels in depressed patients characterized by great stress, features of anxiety, agitation and retardation; and there is a positive correlation between the degree of adrenal cortical overactivity and independent ratings of depression for a large proportion of the patients studied.
However, in a very recent publication, Sachar (60) pointed out that urinary 17-OHCS excretion dropped only slightly following recovery and that the corticosteroid changes were not commensurate with and did not correlate with the severity or course of the depressive illness. The urinary 17-0HCS response to hospital admission far exceeded the change from illness to recovery. Seven of the twenty patients he studied had lower urinary 17-0HCS levels during illness than after recovery. In ten patients plasma 17-0HCS levels were also measured and they dropped slightly but not significantly following recovery. His findings suggested that depressive illness per se had little effect on adrenal cortical function. He pointed out that this was at variance with some reports in the literature, but that many studies had failed to take into account the important control issues such as the adrenal cortisol response to hospital admission and the interference of certain medications.
Other investigators using different measures of adrenocortical activity have advanced different interpretations of pituitary adrenocortical function in severe depressions. Kurland (38, 39) studied urinary 17-0HCS and 17-ketogenic excretion in ten depressed subjects. He reported elevations in the 17-ketogenic steroids which correlated well with the severity of the depression while the 17-OHCS did not. The author hypothesized an increased corticosteroid turnover rate in the liver during depression which resulted in a faster metabolism of cortisol and cortisone through their dihydroand tetrahydro-derivatives to cortol and cortolone. In the urine the parent compounds were detected as hydroxycorticosteroids and ketogenic steroids but cortol and cortolone were detected as ketogenic steroids only. He felt that the correlation between the clinical state and the 17-ketogenic steroids could be explained by postulating a faster turnover of corticosteroids in depression with a return to normal with recovery since this would mean a slower production of cortol and cortolone. In support of his interpretation, Kurland quotes Persky (48, 49) who found an increased rate of cortisol breakdown in anxious patients. More recently Kurland (40) successfully treated a heterogeneous group of twelve patients who were previously unresponsive to antidepressant medication with an artificial glucocorticoid, prednisone. He felt that this added further supporting evidence for the possibility of a relative deficiency of cortisol in depression.
Jakobson in 1966 (32) reported an increase in the excretion of compound S in depressed patients. This precursor of cortisol has a low glucocorticoid activity. He suggested that this increased excretion could result from an alteration of normal steroid metabolism similar to that caused by the administration of blocking agents such as metopirone. These alterations in steroid metabolism are known to occur in conditions such as congenital adrenal hyperplasia. This finding also supports the hypothesis of Kurland.
An apparent paradox has therefore arisen with regard to-the endocrine findings in depressive illness. Some investigators postulate a state of hyperadrenocorticism while others postulate a state of relative adrenocortical hypofunction in severe depression.
Our knowledge of the adrenocortical response in mania is equally paradoxical. Rizzo et al (57) found low urinary glucocorticoids in a manic depressive female patient during her hyperactive episodes with the levels returning to normal after clinical recovery. Gibbons and McHugh (25) reported a case with high plasma cortisol levels during phases of depression and low levels during phases of mild elation. Bunney et al (10) studied the behaviour and urinary 17-0HCS in a female patient with regular 48-hour manic depressive cycles over a two-year period. The patient's mania was characterized by intense denial of her illness and was accompanied by low 17-0HCS levels. Her days of depression were associated with feelings of suffering and pain and her 17-0HCS levels were high. Bunney and his associates felt that these findings supported the concept that the mechanism of denial is associated with low levels of 17-hydroxycorticosteroids.
In contrast to these findings, Schwartz et al (67) studied a 48-year old female manic depressive patient through a complete 42-day cycle. They found that both manic and depressed phases were associated with increased urinary excretion of 17-hydroxycorticosteroids which suggested to them that the manic state is associated with peak elevations of corticoid excretion. Bliss et al (5) reported a four-month study of a schizophrenic patient who showed agitated and hypomanic behaviour. On admission to hos-pital, the patient was hyperactive and had high plasma 17-hydroxycorticosteroid levels. These levels remained high but dropped later when the patient settled down.
These high levels reported in the last two papers during the hypomanic behaviour of patients are in contrast to the previous studies mentioned.
Let us now turn to a consideration of the catecholamines. The function of norepinephrine, dopamine and serotonin in the brain has interested investigators for over a decade. This was triggered by the observation that these substances could be influenced by psychopharmacological agents. Because of this interest, we have in the last few years gathered important new information about the cerebral amines and their functions (68) . Pharmacological treatments for depression so far suggest that the tricyclic compounds and the monoamine oxidase inhibitors increase the functionally free norepinephrine in the brain and that the antihypertensive drugs, reserpine and methyldopa, decrease free cerebral norepinephrine and cause clinical depression (34, 62, 11) .
Rosenblatt et III in 1959 (59) suggested that changes in brain norepinephrine may be involved in depression. Their hypothesis was that the depressive state might be associated with a relative decrease of norepinephrine or serotonin, although they have hitherto lacked direct evidence for its support. Kopin and Gordon (35) have shown in animals that normetanephrine excretion may reflect noradrenergic activity. Schildkraut et III (63, 64, 65) observed a rise in normetanephrine excretion during clinical improvement in depressed patients treated with imipramine. In the retarded patient normetanephrine was lower before treatment than after treatment. Increased excretion of normetanephrine was observed in one patient during a hypomanic phase. The implication is that if the Kopin-Gordon hypothesis applies in humans, clinical improvement from depression is associated with increased noradrenergic activity and that noradrenergic activity is decreased in retarded depressions and increased in mania (63, 33, 66) . Caution however must be exercised in the interpretation of these results since only a small fraction of the urinary norepinephrine or normetanephrine comes from the brain, nevertheless it is possible that catecholamine metabolism in the periphery may in fact reflect changes in the brain.
There is also a great deal of evidence to show that the reaction of the catecholamines depends upon the presence of the adrenal steroids. So let us consider some of the evidence that these two groups of hormones interact with each other.
Adrenalectomized dogs maintained on cortical extract responded to pressor influences in a substantially normal way (2) and those in which the extract was withdrawn had a diminished response (13). The conclusion drawn from these experiments was that the adrenal cortex was concerned with the capacity of the animal to respond to sympathomimetic substances (56, 14) . There is also evidence that epinephrine or nerve stimulation in adrenalectomized animals increases the demand for cortical hormone and that sympathectomized-adrenalectomized dogs need less cortical hormones for maintenance (41) .
Wurtman and Axelrod (70) demonstrated in animals that adrenal steroids enhance the activity of the enzyme which converts norepinephrine into epinephrine in the adrenal medulla. Ramey and Goldstein (55) in discussing the relationship between the cortical steroids and epinephrines put forward the suggestion that the steroids are 'permissive' for the action of the epinephrines and that in their absence, the threshold for epinephrine and norepinephrine action is raised. They also point out that corticosteroids may play a role in the transmission of impulses in the central nervous system by the potentiation of neurohormonal effects. The neurohormones would include the epinephrines, serotonin and acetylcholine and the steroids have been shown to affect the reaction of all these substances (3, 27, 53) .
From clinical studies there is also some indirect evidence of a close relationship between the action of norepinephrine and the cortical steroids. Kurland and Freedberg (37) demonstrated in normotensive subjects that there was a striking potentiation of the blood pressure response to norepinephrine within 24 hours after the administration of ACTH or cortisone and that the potentiating effect disappeared within 36 hours after the omission of these agents. They felt their data were consistent with the hypothesis that ACTH increases the pressor response to norepinephrine by the release of C-ll-oxysteroids from the adrenal cortex and that cortisone alone was equally effective in increasing sensitivity to norepinephrine. Prange et at (54) studied the systolic blood pressure response of depressed patients to infused norepinephrine. They found in all 38 cases that the norepinephrine pressor response was clearly related to clinical improvement, i.e. that after clinical recovery there was a greater systolic blood pressure response to infused norepinephrine. A case reported by Cumming and Kort (17) may be an example of the relationship between adrenal cortical deficiency and depression. They found an Addisonian patient with an agitated psychotic depression which was refractory to twelve electroconvulsive treatments. However, after he was placed on hydrocortisone, the patient made a dramatic recovery responding to two E.C.T.'s and maintaining his improvement. Electroconvulsive therapy may owe its beneficial effects to an alteration in catecholamine metabolism since elevation in plasma and urinary norepinephrine and epinephrine has been reported after it has been given without an anaesthetic or muscle relaxant, i.e. unmodified E.C.T. (69, 16, 31) . Whether or not in this instance of Cumming and Kort the steroids facilitated a favourable response to E.C.T. cannot be decided but such unique instances sometimes provide unexpected results. E.C.T. does however affect the amines in other organs and indirect methods strongly suggest that it also does in the brain.
Let us now turn to our own research project which is designed to investigate the possibility of an imbalance between the adrenocorticosteroids and the catecholamine hormone systems in psychotic depression. This is a preliminary report in which the findings of the first four patients will be discussed. The initial clinical rating was done with the Hamilton Depression Rating Scale (28); the Depressive Scale of the MMPI; and the Rorschach Test; and weekly thereafter by the Hamilton Scale only. All four were suffering from a psychotic depressive illness (44, 42) , two were male, two were female with a mean age of 59 years. The subjects were in good physical health and all suitable for E.C.T.
Each patient was free from medication for at least two weeks prior to this study. For the first 72 hours of their admission to hospital, each candidate was placed on placebo three times daily and once at bedtime. After the pre-treatment laboratory collections and clinical assessments were made, the patients were placed on dexamethasone 0.75 mgm. at midnight (47) . This glucocorticoid was continued for a varying period of time in order to observe the effects of the medication on the clinical picture. Imipramine 150 mgm. daily in divided doses was then added.
Pre-treatment 24-hour urines were collected and concurrently 10 cc of heparinized venous blood was drawn over a twenty-four hour period at 7.45 a.m., 11.45 a.m. and 10.00 p.m. for the estimation of plasma and urinary cortisol levels. These procedures were then repeated at weekly intervals. The method of estimating the cortisol in the plasma and the urine was that devised by Murphy (43) . The investigation can be divided into three phases (Tables 1, 2 , 3, 4) . Phase I This corresponded to the pre-treatment period and lasted 12 hours in all cases. The patients were given placebo during this time and the initial clinical and biochemical studies were completed.
The Hamilton Rating values were high with an average score of 12.5, indicating the presence of a severe depression in each case.
The cortisol values were elevated in two patients (nos. 2 and 3) and within normal limits in the other two (nos. 1 and 4), Phase II After completing Phase I, the patients were then placed on dexamethasone 0.75 mgm. at midnight and the placebos were continued as before. Since it was not known what effect this medication would have on the depressive picture the duration of the phase varied. In cases 1 and 2 it was continued for four weeks. During this time the limited effects of dexamethasone could be observed so the phase was reduced to three weeks in the third patient and two weeks in the fourth. The results were similar and equally effective. The dexamethasone suppressed the ACTH secretion and hence lowered the plasma and urinary values of cortisol. In the normal person the lowest levels of plasma cortisol are found between 10.00 p.m. and 2.00 a.m., then there is a gradual elevation until 4.00 a.m., followed by a steeper rise until maximum values are reached between 6.00 a.m, and 8.00 a.m.; the values then fall steadily until noon and more slowly until 10.00 p.m. where they remain approximately steady until 2.00 a.m. when the cycle starts anew (51, 4) . In patients 1, 2 and 4 these values were low or undetectible; in patient no. 3 the values, although not reduced to this extent, were considerably suppressed. The clinical rating scores improved during this phase (average 48.5) but they could not be reduced further.~e fall in the scale values was due to Improvement in the sleep rhythm, which was disturbed in each subject and which returned to normal within 10-14 days; psychomotor reta.rdation present in. p~ tients 1 and 3 disappeared also within this period; the appetite rhythm returned in all cases within two weeks and there was a major improvement in somatic complaints. The primary depressed mood itself remained unchanged, together with suicidal ruminations and feelings of guilt and self-reproach, symptoms which were present in all cases.
It generally takes between 10-21 days for imipramine to act, but in these patients there was a response within 72 hours during which the depressed mood lifted. At the end of one week the patients were discharged home and returned to their occupation or household duties, as was the case.
The combination of dexamethasone and imipramine appeared to be a very favourable one in the treatment of psychotic depression. Using the combined therapy of an antidepressant medication (imipramine or amitriptyline or monoamine oxidase inhibitor, e.g. isocarboxazid) and dexamethasone, an additional 13 patients, making 17 in all, have been studied. All have responded favourably and quickly to the combined treatment plan. There is a marked improvement in the mood of the patient within one week of starting the combined therapy and all patients have been discharged within four weeks from the hospital clinically recovered. Maintenance therapy with the antidepressant medication alone is continued after discharge. The response is much swifter than that using imipramine alone. It would appear that the dexamethasone is a primer for imipramine in some way. We are at present starting our control series of patients in which a placebo will be used with dexamethasone in a double blind trial.
To explain these findings let us consider what might be happening to these patients. From animal and clinical studies previously mentioned in this text, we know that there is no direct evidence that the steroids affect the activity of the brain amines. However, there is a great deal of indirect evidence that they do. The presence of steroids is essential for the proper functioning of compounds considered to be the chemical transmitter substances in the brain, namely norepinephrine, epinephrine, serotonin and acetylcholine, and hence by implication they are thought to play a role in the transmission of nerve impulses by potentiating the action of these neurohormones.
The findings from animal experiments (50, 19) show that the adrenal cortex is the source of brain steroids and that the central concentration varies directly with the peripheral concentration of these hormones. This has suggested to some investigators (22) that small changes in plasma cortisol levels might significantly change the steroid concentration in the human brain. A considerable amount of knowledge now indicates that depressive illness per se does not cause the adrenocortical overactivity that was concluded from earlier studies and that overactivity, if it does occur, is most probably due to the presence of anxiety brought on by emotional stresses. Furthermore there are reports of increased degradation of cortisol or an alteration in normal cortisol synthesis producing a deficiency of steroid rather than an excess in depressive illnesses. Any deficit then in the peripheral circulation will be reflected markedly in the brain and this shortage of steroid will affect the functioning of the neurohormones; and we can surmise from an important school of thought that there is probably a lack of central amines in depression. The authors feel then that there is a reasonable possibility that the biochemical state of the depressed patient might be a relative or absolute deficiency of both central corticosteroids and catecholamines.
If the hypothesis is correct, the replacement of physiological amounts of steroid in the form of dexamethasone will produce a favourable milieu for the proper functioning of the brain amines. The imipramine (or other antidepressant medication) provides the necessary central catecholamine which is then able to act immediately at the brain tissue level.
The results so far indicate that in psychotic depressive illness we are obtaining a much swifter clinical response with dexamethasone and imipramine combined than one normally does with imipramine alone. The explanation for these findings appears to be in the favourable interaction between the steroids and the brain catecholamines. Resume L'auteur decrit un traitement en deux etapes de la psychose depressive, traitement qui produit une reaction clinique beaucoup plus rapide que celle qu'on peut obtenir au moyen des modes ordinaires d'administration de medicaments qui abaissent l'activite fonctionnelle.
L'etat biochimique du malade deprime semble etre une deficience tant des adrenocorticosteroides que des catecholamines du systerne central. L'administration de dexamethasone produit un remplacement des quantites physiologiques de steroides, ce qui cree un milieu favorable au bon fonctionnement des amines cerebrales, Les medicaments antideprimants (imipramine, amitryptiline ou isocarboxazide) foumissent les catecholamines centrales necessaires qui peuvent alors agir immediatement au niveau des tissus cerebraux, Dix-sept malades en tout, a qui on a administre ce double traitement, ont presente une bonne reaction. lIs ont tous recu leur conge de l'hopital en moins de quatre semaines, a la suite de leur guerison clinique.
De faibles doses physiologiques (Omg 75) de dexamethasone ont ete administrees aminuit afin d'enrayer la secretion d'ACTH de la glande hypophysaire, juste avant Ie debut de sa secretion diume.
Le rythme du sommeil, auparavant trouble chez tous les malades, est revenu a la normale dans les 10 a 14 jours; Ie retard psychomoteur a egalement dispam au cours de cette periode; Ie rythme de l'appetit est revenu dans tous les cas, en moins de deux semaines, et les plaintes somatiques ont sensiblement diminue. L'echelle Hamilton de notation de la depression (Hamilton Depressive Rating Scale), utilisee comme base pour les appreciations cliniques hebdomadaires, a rnontre que la depression avait diminue dans une certaine mesure au cours de cette phase, mais qu'elle a atteint un niveau au-dessous duquel il n'y avait plus d'amelioration, L'humeur deprimee ellememe est restee inchangee, tout comme ce qui est arrive pour les idees de suicide, les sentiments de culpabilite et les reproches que les malades se font a euxmemes, symptomes qui eraient presents dans tous les cas.
On ajouta alors de I'imipramine en doses quotidiennes divisees de 150 mg. Ce medicament, regIe generale, ne commence aagir qu'apres 10 a21 jours, mais ces malades presentaient une reaction dans les 72 heures, periode au cours de laquelle I'humeur depressive commencait a se dissiper, Au bout d'une semaine, chaque malade recevait son conge et reprenait ses occupations normales.
